CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 503 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $9,542 | -58.9% | 140 | -62.3% | 0.00% | -66.7% |
Q4 2023 | $23,225 | +37.9% | 371 | 0.0% | 0.00% | +50.0% |
Q3 2023 | $16,840 | -19.1% | 371 | 0.0% | 0.00% | -33.3% |
Q2 2023 | $20,828 | -29.8% | 371 | -43.4% | 0.00% | -25.0% |
Q1 2023 | $29,671 | +109792.6% | 656 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $27 | -99.9% | 656 | 0.0% | 0.00% | -33.3% |
Q3 2022 | $43,000 | +7.5% | 656 | 0.0% | 0.01% | +20.0% |
Q2 2022 | $40,000 | -2.4% | 656 | 0.0% | 0.01% | 0.0% |
Q1 2022 | $41,000 | -18.0% | 656 | 0.0% | 0.01% | 0.0% |
Q4 2021 | $50,000 | +92.3% | 656 | +184.0% | 0.01% | +66.7% |
Q3 2021 | $26,000 | -29.7% | 231 | 0.0% | 0.00% | -25.0% |
Q2 2021 | $37,000 | +32.1% | 231 | 0.0% | 0.00% | +33.3% |
Q1 2021 | $28,000 | -20.0% | 231 | 0.0% | 0.00% | -25.0% |
Q4 2020 | $35,000 | +29.6% | 231 | -27.8% | 0.00% | 0.0% |
Q3 2020 | $27,000 | +50.0% | 320 | -23.8% | 0.00% | +33.3% |
Q1 2020 | $18,000 | -30.8% | 420 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $26,000 | – | 420 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $37,781,000 | 20.21% |
Ariose Capital Management Ltd | 37,900 | $2,872,000 | 6.78% |
EcoR1 Capital, LLC | 1,077,483 | $81,652,000 | 2.60% |
NEA Management Company, LLC | 1,590,002 | $120,490,000 | 2.44% |
ARK Investment Management | 9,087,868 | $688,679,000 | 2.08% |
NIA IMPACT ADVISORS, LLC | 62,609 | $3,876,000 | 2.06% |
Deuterium Capital Management, LLC | 18,000 | $1,364,000 | 2.02% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 108,200 | $8,192,000 | 1.82% |
PLUSTICK MANAGEMENT LLC | 50,000 | $3,789,000 | 1.76% |
Nikko Asset Management Americas, Inc. | 4,319,471 | $330,526,000 | 1.74% |